Collaborative care for ocular GVHD

The cGVHD Q&A: Expert Insights in Chronic GVHD Management

This special FAQ episode brings together Dr. Dennis Kim, Hematologist/Oncologist, and Dr. Gizelle Popradi, Hematologist, for an in-depth conversation on what clinicians need to know about cGVHD management. Our experts offer an insightful overview of the evolving frontline algorithm in cGVHD management, including how to select patients for systemic steroids and when to reassess for non-response. They highlight how emerging therapeutic agents are shaping sequential treatment decisions and provide practical guidance on multidisciplinary care and proactive monitoring for multi-organ involvement and early pulmonary changes. The experts also emphasize the importance of incorporating patient-reported outcomes into clinical practice. Tune in to explore clinical pearls on prevention, guideline integration, and evidence-based algorithms, delivering actionable insights to support more patient-centred care. Don’t miss the conversation! The views and opinions expressed in this episode are those of the speakers and do not necessarily reflect the views or positions of any entities they represent. Declaration of conflict of interest: Dr. Gizelle Popradi: · Direct financial relationship, including receipt of honoraria: AbbVie, Amgen, BMS, Daiichi Sankyo, Gilead, Incyte, Jazz, Kyowa Kirin, Mallinckrodt/Therakos, Medexus, Novartis, Paladin, Pfizer, Sanofi, Sean Gen, Servier, Sobi, Takeda. Dr. Dennis Kim: · Direct financial relationship, including receipt of honoraria: Novartis, Sanofi, Jazz, Paladin. Membership on advisory boards or speaker bureaus: Novartis, Sanofi, Jazz, Paladin. Funded grants, research, or clinical trials: Novartis, Sanofi, Jazz, Paladin. MAT-CA-2501632

Bridging pediatric and adult cGVHD care

When it comes to managing chronic graft-versus-host disease (cGVHD), what are the unique considerations for pediatric patients, setting them apart from adult care? Our host, Dr. Kirk Schultz, explores this and other topics with Dr. Henrique Bittencourt, a pediatric hematologist/oncologist and clinical professor at the CHU Sainte-Justine, Université de Montréal. Join our experts as they navigate the distinct landscape of chronic GVHD in children. They explore why pediatric presentations often require unique diagnostic approaches and specialized management strategies, emphasizing the critical role of multidisciplinary collaboration and addressing the challenges of transitioning patients to adult care. Don’t miss the conversation!  The views and opinions expressed in this episode are those of the speakers and do not necessarily reflect the views or positions of any entities they represent.  Declaration of conflict of interest:  Dr. Kirk Schultz: · Membership on advisory board or speakers’ bureaus: Incyte, Sanofi. Patents on a drug, product, or device: cGvHD diagnostic and risk assignment algorithms. Dr. Henrique Bittencourt: · Direct financial relationship, including receipt of honoraria: Jazz. Membership on advisory board or speakers' bureaus: Amgen, Incyte, Jazz, Sanofi. Funded grants, research, or clinical trials: Amgen, AbbVie, Incyte, Novartis, Roche, Sanofi, Syndax. MAT-CA-2501035

Collaborative care for ocular GVHD

How can we best alleviate the significant impact of ocular chronic graft-versus-host disease (cGVHD) on our patients' daily lives and overall well-being? Our host, Dr. Kareem Jamani, explores this and other topics with Dr. Jamie Bhamra, an ophthalmologist specialized in corneal and ocular surface diseases, and Assistant Professor at the University of Calgary. This episode features our experts delving into the frequent presentations of ocular GVHD, the burden this manifestation places on transplant patients, and the importance of collaborative care among multidisciplinary specialists to optimize patient outcomes. They also discuss a multipronged management approach, from initial treatments to advanced interventions for this common, yet sometimes challenging, complication. Declaration of conflict of interest: Dr. Kareem Jamani: * Membership on advisory board or speakers’ bureaus: Jazz, Novartis, Paladin, Sanofi, Servier, Takeda, Vertex. Funded grants, research, or clinical trials: Jazz. Dr. Jamie Bhamra: * None. Don’t miss the conversation! The views and opinions expressed in this episode are those of the speakers and do not necessarily reflect the views or positions of any entities they represent. Declaration of conflict of interest: MAT-CA-2500984

Navigating infectious complications in cGVHD

Chronic graft-versus-host disease (cGVHD) presents a spectrum of often hidden infectious challenges. When should a hematologist managing these complex patients call in an infectious disease specialist? Our host, Dr. Gizelle Popradi, takes a deep dive into this topic with infectious disease expert Dr. Matthew Cheng, clinical researcher and assistant professor at the McGill University Health Centre. In this episode, our experts explore critical considerations for managing infectious complications in patients with cGVHD, from identifying common and atypical infections to diagnostic pathways, and innovative prophylactic and therapeutic strategies. Discover practical insights that will enhance your approach to optimal care in this complex and vulnerable patient population. Don’t miss the conversation! The views and opinions expressed in this episode are those of the speakers and do not necessarily reflect the views or positions of any entities they represent. Declaration of conflict of interest: Dr. Gizelle Popradi: * Direct financial relationship, including receipt of honoraria: AbbVie, Amgen, BMS, Daiichi Sankyo, Gilead, Incyte, Jazz, Kyowa Kirin, Mallinckrodt/Therakos, Medexus, Novartis, Paladin, Pfizer, Sanofi, Sean Gen, Servier, Sobi, Takeda. Dr. Matthew Cheng: * Direct financial relationship, including receipt of honoraria: AstraZeneca, GEn1E Lifesciences, Merck, Nomic Bio, Pfizer, Takeda. Membership on advisory board or speakers' bureaus: GEn1E Lifesciences, Nomic Bio. Funded grants, research, or clinical trials: Canadian Institutes of Health Research, Fonds de Recherche du Québec – Santé, Amplyx Pharmaceuticals, Cidara Therapeutics, SCYNEXIS Inc. Patents on a drug, product, or device: Methods for detecting tissue damage, graft-versus-host disease, and infections using cell-free DNA profiling; methods for assessing the severity and progression of SARS-CoV-2 infections using cell-free DNA. All other investments or relationships: co-founder of Kanvas Biosciences. MAT-CA-2500975

Unpacking the latest Canadian cGVHD guidelines

There are several international guidelines for management of chronic graft-versus-host disease (cGVHD), but what about Canadian-specific guidance on how best to manage this complex disorder? Our podcast moderators, Dr. Gizelle Popradi, hematologist and Stem Cell Transplant Program Director at the McGill University Health Centre, and Dr. Dennis Kim, clinician at the Princess Margaret Cancer Centre, provide exclusive perspectives as authors of the latest consensus-based Canadian cGVHD guidelines. Our experts discuss the rationale and collaborative development process behind the recently published Cell Therapy Transplant Canada (CTTC) guidelines for managing cGVHD. They explore the unique management challenges within the Canadian healthcare landscape, as well as the unmet needs these guidelines aim to address in cGVHD care across the country. Finally, our authors give their insights into the future of cGVHD treatment and how exciting developments in the field can lead to a brighter future for patients. Don’t miss the conversation! The views and opinions expressed in this episode are those of the speakers and do not necessarily reflect the views or positions of any entities they represent. Declaration of conflict of interest: Dr. Gizelle Popradi: * Direct financial relationship including receipt of honoraria: Sanofi, Servier, Mallinckrodt, AbbVie, Jazz, Medexus, Pfizer, Seattle Genetics, Takeda, Amgen, Merck, Gilead, Novartis, Kyowa Kirin, Paladin, Sobi. Funded grants, research, or clinical trials: Mallinckrodt, Syndax, AbbVie, Equillium, Amgen, Incyte. Dr. Dennis Kim: * Direct financial relationship including receipt of honoraria: Novartis, Sanofi, Pfizer, Jazz, Paladin. Membership on advisory board: Novartis, Sanofi, Jazz, Paladin. Funded grants, research, or clinical trials: Novartis, Sanofi, Jazz, Paladin. MAT-CA-2401072